ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1552

Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis

Hugh Alessi1, Yiming Luo1, Kaitlin Quinn2 and Peter Grayson3, 1NIH, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

Meeting: ACR Convergence 2022

Keywords: genetics, genomics, Takayasu.s arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: A set of genes has been associated with aortopathies, which are defined as non-inflammatory diseases where the integrity of large arteries is compromised leading to dilatation, aneurysm, and dissections. Overlap can exist between the clinical features of aortopathies and Takayasu’s arteritis (TAK), a form of large vessel vasculitis characterized by vascular inflammation of the aorta and branch vessels. Genetic aortopathy panels are commercially available; however, the clinical utility of such screening in patients with TAK is unclear. We hypothesized (1) that genes implicated in aortopathies could be involved in the pathogenesis of TAK and (2) that rare variants in specific genes may be associated with clinical features in TAK.

Methods: Patients with TAK and healthy controls were sequenced via whole exome sequencing. A list of aortopathy genes was chosen based upon their inclusion in one of 10 commercial aortopathy panels. Genetic sequencing data and identified rare variants were subject to quality control steps ensuring sufficient read depth and coverage harmonization between patients and controls. Rare variants in these genes were then evaluated in two steps. First, a series of gene-level burden tests comprising 16 models of genetic variation was used to compare the burden of rare variants in TAK versus healthy controls. Second, patients were evaluated for the presence of a clinical feature associated with one of six phenotypic groupings: aneurysm, occlusion, surgery, myocardial infarction, stroke, and thromboembolism. The burden of rare variants in aortopathy genes was then examined in TAK patients with and without a qualifying clinical feature. Firth’s Logistic Regression, Fisher’s Exact test, and Optimal Sequence Kernel Association Test (SKAT-O) were used for burden testing. A significance cut-off for gene-level burden tests was set at 5.0 x 10-5, and significance for phenotype associations was set at p < 0.0083 using Bonferroni correction.

Results: Rare variants were examined in 62 aortopathy genes in 153 patients with TAK and 2923 healthy controls. No genes were found to be significantly associated with TAK (FIGURE 1). For the phenotype association analysis, rare variants in COL4A5 were significantly associated with surgical intervention (arterial graft or valve replacement) in TAK (p = 0.0007). Variants in ADAMTS2 were significantly associated with stroke in TAK (p = 0.008) (FIGURE 2).

Conclusion: While rare variants in genes associated with aortopathies are present in TAK, there is not a significantly greater burden of rare variants in these genes in patients with TAK compared to healthy controls. Commercial aortopathy gene panel testing thus does not appear to yield any benefit to the clinical management of patients with TAK. Many variants with uncertain significance were identified, and two gene-phenotypic groupings were discovered. Continued research into potential functional roles of these genes in TAK is warranted. Future studies with larger numbers of patients may be better powered to identify clinically meaningful rare variant associations in TAK.

Supporting image 1

Figure 1. Burden test results for 62 aortopathy genes across 16 statistical models

Supporting image 2

Figure 2. Phenotyopic associations with rare variants in aortopathy genes


Disclosures: H. Alessi, None; Y. Luo, None; K. Quinn, None; P. Grayson, None.

To cite this abstract in AMA style:

Alessi H, Luo Y, Quinn K, Grayson P. Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/rare-variant-analysis-of-aortopathy-genes-in-takayasus-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rare-variant-analysis-of-aortopathy-genes-in-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology